Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

UPCC 04219 Phase 2 Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2/3 Neuroendocrine Tumors

Next Previous
Trial Profile

UPCC 04219 Phase 2 Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2/3 Neuroendocrine Tumors

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Temozolomide (Primary) ; Yttrium-90 (Primary)
  • Indications Liver metastases; Neuroendocrine tumours
  • Focus Therapeutic Use
  • Acronyms UPCC 04219

Most Recent Events

  • 04 Jun 2026 Planned End Date changed from 1 May 2026 to 1 Jul 2028.
  • 04 Jun 2026 Planned primary completion date changed from 1 May 2026 to 1 Jul 2028.
  • 28 Aug 2025 Planned number of patients changed from 50 to 70.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top